Insight: Flow Blockchain Rollback Decision Made Without Major Bridge Partner Communication, Potential Economic Loss Far Exceeds Vulnerability Itself
BlockBeats News, December 28, deBridge co-founder Alex Smirnov posted on the X platform stating that the Flow team has decided to roll back the blockchain and claimed to be in a forced sync window with key ecosystem partners (bridges, centralized exchanges, decentralized exchanges). As one of the main bridge providers for Flow, deBridge has not received any communication or coordination from the Flow team, posing significant risk. Alex Smirnov stated that the hasty chain rollback could result in economic losses far exceeding the impact of the original attack, introducing systemic issues that would affect bridges, custodians, users, and counterparties who acted honestly during the affected window. Alex Smirnov urged all Flow validators to cease transaction validation on the rollback chain until clear compensation plans, ecosystem partner coordination, and security team involvement are established. Current RPC responses indicate that the Flow status has been rolled back but is not yet accepting new transactions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google Cloud officially launches Claude model deployment option managed by Anthropic

SpaceX says any potential merger with Tesla still requires further approval

Moderna plunges by as much as 26%, setting a record for the biggest single-day drop! Melanoma vaccine data leaked early, results fall short of expectations
Clinical trial data from phase 3 of the personalized melanoma vaccine jointly developed by Moderna and Merck was unexpectedly leaked ahead of schedule. The data showed a 42% reduction in cancer recurrence risk and a 38% reduction in risk of distant metastasis. These results fell short of market expectations, as an earlier study had shown the combination therapy could reduce recurrence risk by 49% and distant metastasis risk by 59%. Moderna's stock price plunged as much as 26% intraday, later rebounded partially, and ultimately closed down 17.6%.
